Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection.

摘要: We investigated the effects of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) administered by subcutaneous route, first alone and then alternating with azidothymidine (AZT), in leukopenic patients severe immunodeficiency virus (HIV) infection. Ten acquired syndrome (AIDS) or related disorders, five whom could not tolerate conventional doses AZT, were rGM-CSF subcutaneously for 12 days. They an regimen using AZT 1 week, followed 5 days 2 without any medication. During initial GM-CSF administration, there was increase mean white blood cell (WBC) value. In addition, stimulated circulating monocytes as evidenced superoxide anion production expression surface HLA-DR antigen. However, at same time increased serum HIV p24 antigen each six evaluable from 189 x/divided 2.02 pg/mL (geometric SEM) entry to 375 2.11 (P less than .05). subsequent period treatment, fell below day 14 value most patients, particularly after weeks administration. The T4 who had previously received but generally did change those prior exposure. Hematologic toxicity appeared be somewhat reduced compared continuous full-dose therapy, two previous hematologic tolerated this 25 weeks. Additional regimens simultaneously combining these agents are worth exploring.